Moreover, HER2-postive breast cancer are at high risk of developing metastatic disease, particularly in brain which may develop in up to half of patients (Gabos et al., 2006; Leyland-Jones, 2009; Olson et al., 2013; Martin et al., 2017). This evidence concerns the gene ERBB2 and breast cancer.